Thursday, December 11th, 2025: Day Three - ET (Eastern Time, GMT-05:00)
Gain actionable insights on WAC optimization strategies, pricing governance models and access-driven pricing approaches that drive both commercial success and patient affordability
Manage the gross-to-net bubble across diverse product portfolios including branded pharmaceuticals, generics and biosimilars to maximize financial performance
Understand financial reporting risks associated with complex distribution channel dynamics
- Jeffrey R. Miller, CPA, CGMA - VP Finance & Corporate Controller, Lannett Company
- Rick Sage - Executive Vice President, Innovation & Standards, National Council for Prescription Drug Programs, Inc. (NCPDP)
Explore how to maximize the potential of existing commercial structures and teams to secure assets with commercial potential
Understand how to position your company to navigate future market volatility and events, ensuring long-term growth and stability
Discover the benefits of forming strategic partnerships, joint ventures and alliances to drive growth and share risks in the pharmaceutical market
Examine the rapidly evolving digital therapeutics market, including growth projections, regulatory developments and emerging therapeutic areas showing highest adoption potential
Discover optimal distribution models for digital health products, from direct-to-provider pathways to pharmaceutical partnerships, payer integration and consumer-directed approaches
Learn effective collaboration frameworks between digital therapeutic companies and channel partners, including value creation strategies, revenue models and integration best practices